Tirofiban hydrochloride monohydrate is primarily used in the medical field as an antiplatelet agent. It is administered to prevent blood clots in patients with acute coronary syndrome or those undergoing percutaneous coronary intervention (PCI). By inhibiting platelet aggregation, it reduces the risk of thrombotic events such as heart attacks. It is often used in combination with other medications like heparin to enhance its effectiveness. The drug is typically given intravenously in a hospital setting under close medical supervision to ensure proper dosing and monitor for potential side effects such as bleeding. Its rapid onset of action makes it particularly useful in emergency situations where immediate intervention is required.